REFERENCES
- Agarwal, A. K., Rewari, B. B. & Goel, N. (2000). Drug prescribing in pregnancy. Current Practice in Obstetrics and Gynaecology., 1., 57–73.
- Alghasha, A. A. & Nahata, M. C. (2000). Clinical use of fluoroquinolones in children. Annals of Pharmacotherapy., 34, 347–358.
- Divo, A. A., Sartorelli, A. C., Patton, C. L. & Bia, F. J. (1988). Activity of fluoroquinolone antibiotics against P. falciparumtalic> in vitro. Antimicrobial Agents and Chemotherapy., 32, 1182-1186.
- Edwards, G., Looareesuwan, S., Davies, A. J., Wattanagoon, Y., Phillips, R. E. & Warrell, D. A. (1988). Pharmacokinetics of chloroquine in Thais: plasma and red cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria. British Journal of Clinical Pharmacology., 25, 477-485.
- Foster, S. (1994). Economic prospects for a new antimalarial drug. Transactions of the Royal Society of Tropical Medicine and Hygiene., 88, 55–56.
- Gorrod, J. W. & Beckett, A. H. (Eds) (1978). Drug Metabolism in Mantalic>. London: Taylor and Francis.
- Gupta, K. Hooton, T. M., Wobbe, C. L. & Stamm, W. W. (1999). The prevalence of antimicrobial resis-tence among uropathogens causing acute uncompli-cated cystitis in young women. International Journal of Antimicrobial Agents., ., 305-308.11
- Kozubek, A., Gubernator, J., Przeworska, E. & Stasiuk, M. (2000). Liposomal drug deliveries, a novel approach: plarosomomes. Acta Biochimica Polonica., 47, 639–649.
- Mahmoudi, N., Ciceron, L., Franetich, J. F., Farhati, K., Silvie, O., Eling, W., Sauerwein, R., Danis, M., Mazier, D. & Derouin, F. (2003). In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodiumtalic> spp. Antimicrobial Agents and Chemotherapy., 47, 2636–2639.
- Rieckmann, K. H., Sax, L. J., Campbell, G. H. & Mrema, J. E. (1978). Drug sensitivity of Plasmodium falciparumtalic: an in-vitro microtechnique. Lancet., i, 22–23.
- Rollof, J. & Vinge, E. (1993). Neurologic adverse effects during concomitant treatment with ciproflox-acin, NSAIDs, and chloroquine: possible drug interaction. Annals of Pharmacotherapy., 27, 1058–1059.
- Talan, D. A., Stamm, W. E., Hooton, T. M., Moran, G. J., Burke, T., Iravani, A., Reuning-Scherer, J. & Church, D. A. (2000). Comparison of ciprofloxacin (7 days) and trimethoprim—sulphamethoxazole (14 days) or acute uncomplicated pyelonephritis in women. Journal of the American Medical Association, 283, 1583–1590.
- Trager, W. & Jensen, J. B. (1976). Human malaria parasites in continuous cultures. Science, 193, 673–675.
- Tripathi, K. D., Sharma, A. K., Valecha, N. & Kulpati, D. D. (1993). Curative efficacy of norfloxacin in falciparum malaria. Indian Journal of Medical Research., 97, 176–178.
- Watt, G., Shanks, G. D., Edstein, M. D., Pavanand, K., Webster, H. K. & Wechgritaya, S. (1991). Ciprofloxacin treatment of drug resistant falciparum malaria. Journal of Infectious Diseases., 164, 602–604.
- Wemsdorfer, W. H. (1980). Field evaluation of drug resistance in malaria. In vitro micro-test. Acta Tropica., 37, 222–227.
- Wiesner, J., Henschker, D., Hutchinson, D. B., Beck, E. & Jomaa, H. (2002). In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrobial Agents and Chemotherapy., 46, 2889–2894.
- Wilson, C., Gisvold, O. & Dolige, R. (1971). Textbooktalic> of Organic Medicinal and Pharmaceutical Chemistry. Philadelphia, PA: J. B. Lippincott.
- Yeo, A. E. & Rieckmann, K. H. (1994). Prolonged exposure of Plasmodium falciparumtalic> to ciprofloxacin increases anti-malarial activity. Journal of Parasitology., 80, 158-160.